[Ip-health] Update from India on Xtandi (Enzalutamide) for cancer treatment
leenamenghaney at gmail.com
Mon May 8 09:27:51 PDT 2017
High prices are not charged in the US alone. The drug enzalutamide branded
as Xtandi is sold at Rs 335,000 (over 5000 USD) for a pack of 112 capsules
which is 28 days’ supply. According to KEI generic competition for
enzalutamide could easily drive the price per pill at well less than $.50
per pill, or $2 per day.
In an effort to prevent the marketing of potentially affordable versions of
enzalutamide from India, the University of California – the original
applicant of the patent – through its regents (board) has now filed a
petition before the Delhi High Court [The Regents of the University of
California versus Union of India and Ors, WP (Civil) No. 1163 of 2017].
The writ (petition) is pushing to get the patent application remanded back
to the patent office for re-examination which then leads to increased
pressure on the Indian patent office to grant it.
To read more on the patent opposition and the subsequent dispute before the
Indian court please see
More information about the Ip-health